Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus UTIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus UTIMOX.
LAROTID vs UTIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
For UTIMOX (amoxicillin/clavulanate), typical adult dose is 875 mg/125 mg orally every 12 hours or 500 mg/125 mg orally every 8 hours, depending on infection severity.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 8-12 hours in severe impairment (CrCl <30 mL/min).
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Primarily renal (85-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic